Advertisement

Zahi Mitri, MD, MS

Articles

HER2-low Breast Cancer: Practical Applications of ADC Therapy

December 9th 2021

Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.

Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates

December 9th 2021

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

Strategies in Identifying and Stratifying HER2 Status in Breast Cancer

December 9th 2021

Focused discussion on the methods used to identify a patient’s HER2 status and why it is important to investigate in patients with breast cancer.

Current Landscape of HER2 Testing in Breast Cancer

December 9th 2021

Shared insight on the current state of HER2 classification and testing and in breast cancer, with respect to how it may influence future treatment approaches.

Dr. Mitri on Developments in HER2+ Breast Cancer

September 24th 2021

Zahi Mitri, MD, MS, discusses developments in the treatment of patients with HER2-positive breast cancer.

Dr. Mitri on the Treatment Landscape of HER2+ Breast Cancer

June 29th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the treatment landscape of HER2-positive breast cancer.

Dr. Mitri on Neratinib and Pertuzumab in HER2-Amplified Breast Cancer

June 19th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.

Advertisement
Advertisement